Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Docetaxel
Sanofi
L01CD02
Docetaxel
20mg/1ml
Solution for infusion
Intravenous
No Controlled Drug Status
Valid as a prescribable product
BNF: ; GTIN: 5000283653783
18/10/2016 12:06 - VISTAlink folder 2310353 - Page 1/3 DRIVING AND USING MACHINES No studies on the effects on the ability to drive and use machines have been performed. TAXOTERE CONTAINS ETHANOL (ALCOHOL) This medicinal product contains 50 vol % ethanol anhydrous (alcohol), i.e. up to 1.58 g ethanol anhydrous per vial, equivalent to 40 ml of beer or 17 ml wine per vial. Harmful for those suffering from alcoholism. To be taken into account if you are pregnant or if you are breast-feeding women, in children and high-risk groups such as patients with liver disease, or epilepsy. The amount of alcohol in this medicinal product may have effects on the central nervous system (the part of the nervous system that includes the brain and spinal cord). The amount of alcohol in this medicinal product may alter the effects of other medicines. The amount of alcohol in this medicine may impair your ability to drive or use machines. 3. HOW TO USE TAXOTERE TAXOTERE will be administered to you by a healthcare professional. USUAL DOSE The dose will depend on your weight and your general condition. Your doctor will calculate your body surface area in square meters (m²) and will determine the dose you should receive. METHOD AND ROUTE OF ADMINISTRATION TAXOTERE will be given by infusion into one of your veins (intravenous use). The infusion will last approximately one hour during which you will be in the hospital. FREQUENCY OF ADMINISTRATION You should usually receive your infusion once every 3 weeks. Your doctor may change the dose and frequency of dosing depending on your blood tests, your general condition and your response to TAXOTERE. In particular, please inform your doctor in case of diarrhoea, sores in the mouth, feeling of numbness or pins and needles, fever and give her/him results of your blood tests. Such information will allow her/him to decide whether a dose reduction is needed. If you have any further questions on the use of this medicine, ask your doctor, or hospital pharmacist. 4. POSSIBLE SIDE EFFECTS Like all medic Read the complete document
OBJECT 1 TAXOTERE 80MG/4ML CONCENTRATE FOR SOLUTION FOR INFUSION Summary of Product Characteristics Updated 04-Nov-2016 | SANOFI 1. Name of the medicinal product TAXOTERE 80 mg/4 ml concentrate for solution for infusion 2. Qualitative and quantitative composition Each ml of concentrate contains 20 mg docetaxel (as trihydrate). One vial of 4 ml of concentrate contains 80 mg of docetaxel. Excipient with known effect: Each vial of concentrate contains 2 ml of ethanol anhydrous (1.58 g). For the full list of excipients, see section 6.1. 3. Pharmaceutical form Concentrate for solution for infusion (sterile concentrate). The concentrate is a pale yellow to brownish-yellow solution. 4. Clinical particulars 4.1 Therapeutic indications Breast cancer TAXOTERE in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with: • operable node- positive breast cancer • operable node-negative breast cancer . For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer (see section 5.1). TAXOTERE in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. TAXOTERE monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. TAXOTERE in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease. TAXOTERE in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Prev Read the complete document